Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $109.00 short call and a strike $114.00 long call offers a potential 48.81% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $109.00 by expiration. The full premium credit of $1.64 would be kept by the premium seller. The risk of $3.36 would be incurred if the stock rose above the $114.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 41.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
Thu, 01 Nov 2018 20:50:08 +0000
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
Novo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript
Thu, 01 Nov 2018 16:36:22 +0000
NVO earnings call for the period ending September 30, 2018.
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
Thu, 01 Nov 2018 15:14:03 +0000
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
Thu, 01 Nov 2018 14:31:02 +0000
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
Thu, 01 Nov 2018 14:29:02 +0000
Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.
Also on Market Tamer…
Follow Us on Facebook